Two months ago, a Senate report suggested that Insys Therapeutics (INSY) provided $2.5 million to a patient advocacy group in order to influence usage and providing of its Subsys opioid painkiller. The link, however, was not fully explored, but a new essay in a bioethics blog takes us a step closer to understanding how that relationship may benefit the company.

To do so requires a familiar exercise: follow the money. But it also helps to understand why Subsys and a handful of similar powerful medications, all of which are forms of fentanyl, are often favored by doctors for treating so-called breakthrough cancer pain.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy